Exelixis, Inc. (EXEL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Chair of the Board | 118.25k | -- | 1948 |
| Dr. Michael M. Morrissey Ph.D. | CEO, President & Director | 2.16M | 3.79M | 1961 |
| Mr. Christopher J. Senner | Executive VP & CFO | 1.06M | 702.51k | 1968 |
| Ms. Susan T. Hubbard | Executive Vice President of Public Affairs & Investor Relations | -- | -- | -- |
| Ms. Laura Dillard | Executive Vice President of Human Resources | -- | -- | -- |
| Dr. Peter Lamb Ph.D. | Executive VP of Scientific Strategy | 909.46k | 10.72M | 1961 |
| Dr. Anne Champsaur M.D. | Senior Vice President of Drug Safety | -- | -- | -- |
| Dr. William Berg M.D. | Senior Vice President of Medical Affairs | -- | -- | -- |
| Ms. Deborah Burke | Senior VP of Finance & Controller | 459.32k | 227.66k | 1956 |
Exelixis, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,310
Description
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Corporate Governance
Recent Events
- Apr 18, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 06, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing